Two CRL letters is tough to overcome. A stock that is below margin. A price that disqualifies most institutional ownership and one big factor: lousy management that first tried to get FDA approval without 36 month data plus management that misleads shareholders with less than truthful updates on their progress.
Add a dash of resistance due to the price fall and you have a perfect recipe for loss.
Did I forget to mention the liquidity problems due to lack of volume? That situation has been a constant for months.
Volume can be rectified by a good piece of press news. The only thing you've said that may turn the rudder on my ship is "management not being truthful with shareholders" I'll investigate this to see how this may have happened. If it was actually a premeditated action or simply a miscommunication.